The trial will assess CHM 2101 in individuals with neuroendocrine tumours, advanced colorectal cancer, and gastric cancer. Credit: Peakstock / Shutterstock.com.

Chimeric Therapeutics has announced plans to commence a Phase IA/B clinical trial of CHM 2101 to treat gastrointestinal cancers.

The move comes after the US Food and Drug Administration (FDA) granted clearance for the company’s investigational new drug (IND) application for the first in class CDH17 chimeric antigen receptor (CAR) T cell therapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The open label, multicentre trial will assess CHM 2101 in individuals with neuroendocrine tumours, advanced colorectal cancer, and gastric cancer. 

Chimeric anticipates commencing subject enrolment in the Phase I portion of the trial next year.

CHM 2101 acts on a cancer target named autologous cadherin 17 (CDH17).

See Also:

CDH17 is linked a poor prognosis and metastasis in gastrointestinal cancers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Preclinical research showed that CHM 2101 was demonstrated to destroy established tumours in seven cancer models, without causing any toxicity to normal tissues. 

Chimeric focuses on developing cell therapies for cancer and has a portfolio comprising autologous CAR T cell therapies and allogeneic NK cell therapies. 

The company is evaluating its assets for various oncology indications, with three clinical programmes underway. It also anticipates launching further clinical programmes this year. 

In addition to CHM 2101, the company’s assets include CHM 1101, a CAR T therapy being studied in a Phase IB clinical trial for recurrent/progressive glioblastoma.

Another asset CHM 0201 is a NK cell therapy, which completed a Phase IA trial for treating blood cancers and solid tumours.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.